Farampator

Farampator
Clinical data
Other namesCX-691; ORG-24448
Legal status
Legal status
Identifiers
IUPAC name
  • 2,1,3-benzoxadiazol-6-yl-piperidin-1-ylmethanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H13N3O2
Molar mass231.255 g·mol−1
3D model (JSmol)
SMILES
  • C1CCN(CC1)C(=O)C2=CC3=NON=C3C=C2
InChI
  • InChI=1S/C12H13N3O2/c16-12(15-6-2-1-3-7-15)9-4-5-10-11(8-9)14-17-13-10/h4-5,8H,1-3,6-7H2 ☒N
  • Key:XFVRBYKKGGDPAJ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Farampator (developmental code names CX-691, ORG-24448, SCH-900460) is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator was transferred. The development of farampator was eventually terminated, reportedly due to concerns about cardiac toxicity.[1][2]

Farampator has been investigated for its effect on AMPA receptors and researched for potential use in the treatment of schizophrenia and Alzheimer's disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects such as headache, somnolence and nausea. Subjects reporting side effects had significantly higher plasma levels of farampator than subjects without. Additional analyses revealed that in the farampator condition the group without side effects showed a significantly superior memory performance relative to the group with side effects.[3]

See also

References

  1. ↑ "Farampator - AdisInsight".
  2. ↑ Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". J. Alzheimers Dis. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028.
  3. ↑ Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG (Jun 2007). "Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers". Neuropsychopharmacology. 32 (6): 1272–83. doi:10.1038/sj.npp.1301257. PMID 17119538.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.